Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.
Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D, Hollink IH, Arentsen-Peters ST, van Wering ER, Kaspers GJ, Cloos J, de Bont ES, Cayuela JM, Baruchel A, Meyer C, Marschalek R, Trka J, Stary J, Beverloo HB, Pieters R, Zwaan CM, den Boer ML. Balgobind BV, et al. Among authors: de menezes rx, de bont es. Haematologica. 2011 Feb;96(2):221-30. doi: 10.3324/haematol.2010.029660. Epub 2010 Oct 22. Haematologica. 2011. PMID: 20971820 Free PMC article.
Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J. Pieters R, et al. J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6. J Clin Oncol. 2016. PMID: 27269950
Targeting the reprogrammed metabolism in H3.3K27M pediatric high-grade gliomas.
de Camargo Magalhães ES, de Bont ESJM, Bruggeman SWM, Lima FRS. de Camargo Magalhães ES, et al. Among authors: de bont esjm. Biochim Biophys Acta Mol Basis Dis. 2024 May 20:167248. doi: 10.1016/j.bbadis.2024.167248. Online ahead of print. Biochim Biophys Acta Mol Basis Dis. 2024. PMID: 38777100
Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.
van Dijk AD, Hoff FW, Qiu Y, Hubner SE, Go RL, Ruvolo VR, Leonti AR, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Horton TM, Kornblau SM. van Dijk AD, et al. Among authors: de bont esjm. Cancers (Basel). 2024 Apr 9;16(8):1448. doi: 10.3390/cancers16081448. Cancers (Basel). 2024. PMID: 38672531 Free PMC article.
Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia.
Hurkmans EGE, Klumpers MJ, Dello Russo C, De Witte W, Guchelaar HJ, Gelderblom H, Cleton-Jansen AM, Vermeulen SH, Kaal S, van der Graaf WTA, Flucke U, Gidding CEM, Schreuder HWB, de Bont ESJM, Caron HN, Gattuso G, Schiavello E, Terenziani M, Massimino M, McCowage G, Nagabushan S, Limaye A, Rose V, Catchpoole D, Jorgensen AL, Barton C, Delaney L, Hawcutt DB, Pirmohamed M, Pizer B, Coenen MJH, Te Loo DMWM. Hurkmans EGE, et al. Among authors: de bont esjm. Front Pharmacol. 2023 Jan 9;13:980309. doi: 10.3389/fphar.2022.980309. eCollection 2022. Front Pharmacol. 2023. PMID: 36699085 Free PMC article.
SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin.
Hurkmans EGE, Koenderink JB, van den Heuvel JJMW, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, Groothuismink JM, Vos HI, van der Graaf WTA, Flucke U, Muradjan G, Schreuder HWB, Hagleitner MM, Brunner HG, Gelderblom H, Cleton-Jansen AM, Guchelaar HJ, de Bont ESJM, Touw DJ, Nijhoff GJ, Kremer LCM, Caron H, Windsor R, Patiño-García A, González-Neira A, Saletta F, McCowage G, Nagabushan S, Catchpoole D, Te Loo DMWM, Coenen MJH. Hurkmans EGE, et al. Among authors: de bont esjm. Front Pharmacol. 2022 Nov 9;13:1042989. doi: 10.3389/fphar.2022.1042989. eCollection 2022. Front Pharmacol. 2022. PMID: 36438828 Free PMC article.
Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study.
Hoff FW, Van Dijk AD, Qiu Y, Hu CW, Ries RE, Ligeralde A, Jenkins GN, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Qutub AA, De Bont ESJM, Horton TM, Kornblau SM. Hoff FW, et al. Among authors: de bont esjm. Haematologica. 2022 Oct 1;107(10):2329-2343. doi: 10.3324/haematol.2021.279672. Haematologica. 2022. PMID: 35021602 Free PMC article.
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.
van Dijk AD, Hoff FW, Qiu Y, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, de Bont ESJM, Kornblau SM, Horton TM. van Dijk AD, et al. Among authors: de bont esjm. Proteomics Clin Appl. 2022 Mar;16(2):e2100072. doi: 10.1002/prca.202100072. Epub 2021 Nov 17. Proteomics Clin Appl. 2022. PMID: 34719869 Free PMC article. Clinical Trial.
CREB signaling activity correlates with differentiation and survival in medulloblastoma.
Armandari I, Zomerman WW, Plasschaert SLA, Smit MJ, Martini TEI, de Camargo Magalhães ES, Hogeling SM, Rozema-Huizinga GC, Lourens HJ, Meeuwsen-de Boer TGJ, Scherpen FJG, de Bont ESJM, Bruggeman SWM. Armandari I, et al. Among authors: de bont esjm. Sci Rep. 2021 Aug 9;11(1):16077. doi: 10.1038/s41598-021-95381-0. Sci Rep. 2021. PMID: 34373489 Free PMC article.
156 results